Edition:
India

Champions Oncology Inc (CSBR.OQ)

CSBR.OQ on NASDAQ Stock Exchange Capital Market

8.44USD
1:30am IST
Change (% chg)

$0.11 (+1.32%)
Prev Close
$8.33
Open
$8.25
Day's High
$8.60
Day's Low
$7.89
Volume
8,213
Avg. Vol
16,023
52-wk High
$17.89
52-wk Low
$3.80

Latest Key Developments (Source: Significant Developments)

Champions Biotechnology Q2 Revenue Up 28.6 Pct
Tuesday, 18 Dec 2018 

Dec 17 (Reuters) - Champions Biotechnology Inc ::Q2 REVENUE ROSE 28.6 PERCENT TO $6.7 MILLION.CHAMPIONS BIOTECHNOLOGY INC QTRLY REVENUE OF $6.7 MILLION, UP 28.6%.CHAMPIONS BIOTECHNOLOGY INC - REITERATED FORECAST OF AT LEAST 20% REVENUE GROWTH IN FISCAL 2019 AND SUSTAINED, QUARTERLY OPERATIONAL PROFITABILITY.CHAMPIONS BIOTECHNOLOGY INC QTRLY GAAP EARNINGS PER SHARE $0.02.CHAMPIONS BIOTECHNOLOGY INC QTRLY EPS - NON-GAAP WAS $0.03.  Full Article

Champions Oncology Partners With Puma Biotechnology And Nsabp Foundation On Metastatic Breast And Colon Cancer Co-Clinical Pdx Studies
Monday, 18 Jun 2018 

Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY PARTNERS WITH PUMA BIOTECHNOLOGY AND NSABP FOUNDATION ON METASTATIC BREAST AND COLON CANCER CO-CLINICAL PDX STUDIES.CHAMPIONS BIOTECHNOLOGY - FIRST TRIAL IS PHASE II STUDY OF TRASTUZUMAB EMTANSINE WITH NERATINIB IN WOMEN WITH METASTATIC HER2-POSITIVE BREAST CANCER.CHAMPIONS BIOTECHNOLOGY- SECOND TRIAL IS FOR NERATINIB+TRASTUZUMAB/NERATINIB +CETUXIMAB IN PATIENTS WITH "QUADRUPLE WILD-TYPE" METASTATIC COLORECTAL CANCER.  Full Article

Champions Oncology Reports Record Quarterly Revenue Of $5.2 Million
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY REPORTS RECORD QUARTERLY REVENUE OF $5.2 MILLION.Q2 REVENUE ROSE 16.7 PERCENT TO $5.2 MILLION.SEES FY 2018 REVENUE UP AT LEAST 20 PERCENT.CHAMPIONS BIOTECHNOLOGY INC - REITERATED EXPECTATIONS FOR FISCAL YEAR 2018 REVENUE GROWTH OF AT LEAST 20% OVER FISCAL YEAR 2017.CHAMPIONS BIOTECHNOLOGY INC - QTRLY LOSS PER SHARE $0.01.CHAMPIONS BIOTECHNOLOGY - REITERATES POSITION THAT "IT DOES NOT CURRENTLY INTEND TO RAISE CAPITAL IN THE EQUITY MARKET".  Full Article